Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$4.36 - $6.51 $169,843 - $253,597
-38,955 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$4.7 - $12.06 $183,088 - $469,797
38,955 New
38,955 $183,000

Others Institutions Holding ARAV

About Aravive, Inc.


  • Ticker ARAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,518,300
  • Description
  • Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...
More about ARAV
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.